




Contents lists available at ScienceDirect

Magnetic Resonance Imaging

journal homepage: www.elsevier.com/locate/mri

Imaging biomarkers of lung ventilation in interstitial lung disease from ^{129}Xe and oxygen enhanced ^1H MRI

Marta Tibiletti^a, James A. Eaden^b, Josephine H. Naish^{a,c}, Paul J.C. Hughes^b, John C. Waterton^{a,d}, Matthew J. Heaton^a, Nazia Chaudhuri^e, Sarah Skeoch^f, Ian N. Bruce^{g,h}, Stephen Bianchiⁱ, Jim M. Wild^{b,j}, Geoff J.M. Parker^{a,k,*}

^a Bioxydyn Limited, Rutherford House, Manchester Science Park, Manchester M15 6SZ, United Kingdom

^b POLARIS, University of Sheffield MRI Unit, Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK

^c MCMR, Manchester University NHS Foundation Trust, Wythenshawe, Manchester, UK

^d Centre for Imaging Sciences, University of Manchester, Manchester, UK

^e North West Lung Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

^f Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK

^g NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK

^h Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

ⁱ Academic Directorate of Respiratory Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

^j Insigneo Institute for in silico medicine, Sheffield, UK

^k Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, UK

ARTICLE INFO

Keywords:

Hyperpolarised gas MRI
Oxygen enhanced MRI
Lung MRI
Interstitial lung disease

ABSTRACT

Purpose: To compare imaging biomarkers from hyperpolarised ^{129}Xe ventilation MRI and dynamic oxygen-enhanced MRI (OE-MRI) with standard pulmonary function tests (PFT) in interstitial lung disease (ILD) patients. To evaluate if biomarkers can separate ILD subtypes and detect early signs of disease resolution or progression.

Study type: Prospective longitudinal.

Population: Forty-one ILD (fourteen idiopathic pulmonary fibrosis (IPF), eleven hypersensitivity pneumonitis (HP), eleven drug-induced ILD (DI-ILD), five connective tissue disease related-ILD (CTD-ILD)) patients and ten healthy volunteers imaged at visit 1. Thirty-four ILD patients completed visit 2 (eleven IPF, eight HP, ten DIILD, five CTD-ILD) after 6 or 26 weeks.

Field strength/sequence: MRI was performed at 1.5 T, including inversion recovery T_1 mapping, dynamic MRI acquisition with varying oxygen levels, and hyperpolarised ^{129}Xe ventilation MRI. Subjects underwent standard spirometry and gas transfer testing.

Assessment: Five ^1H MRI and two ^{129}Xe MRI ventilation metrics were compared with spirometry and gas transfer measurements.

Statistical test: To evaluate differences at visit 1 among subgroups: ANOVA or Kruskal-Wallis rank tests with correction for multiple comparisons. To assess the relationships between imaging biomarkers, PFT, age and gender, at visit 1 and for the change between visit 1 and 2: Pearson correlations and multilinear regression models.

Results: The global PFT tests could not distinguish ILD subtypes. Percentage ventilated volumes were lower in ILD patients than in HVs when measured with ^{129}Xe MRI (HV 97.4 ± 2.6 , CTD-ILD: 91.0 ± 4.8 $p = 0.017$, DI-ILD 90.1 ± 7.4 $p = 0.003$, HP 92.6 ± 4.0 $p = 0.013$, IPF 88.1 ± 6.5 $p < 0.001$), but not with OE-MRI. ^{129}Xe reported more heterogeneous ventilation in DI-ILD and IPF than in HV, and OE-MRI reported more heterogeneous ventilation in DI-ILD and IPF than in HP or CTD-ILD. The longitudinal changes reported by the imaging biomarkers did not correlate with the PFT changes between visits.

Data conclusion: Neither ^{129}Xe ventilation nor OE-MRI biomarkers investigated in this study were able to differentiate between ILD subtypes, suggesting that ventilation-only biomarkers are not indicated for this task. Limited but progressive loss of ventilated volume as measured by ^{129}Xe -MRI may be present as the biomarker of

* Corresponding author at: Centre for Medical Image Computing, 1st Floor 90 High Holborn, London WC1V 6LJ, UK.

E-mail address: geoff.parker@ucl.ac.uk (G.J.M. Parker).

<https://doi.org/10.1016/j.mri.2022.10.005>

Received 18 May 2022; Received in revised form 7 October 2022; Accepted 11 October 2022

Available online 15 October 2022

0730-725X/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

focal disease progresses. OE-MRI biomarkers are feasible in ILD patients and do not correlate strongly with PFT. Both OE-MRI and ^{129}Xe MRI revealed more spatially heterogeneous ventilation in DI-ILD and IPF.

1. Introduction

Interstitial lung diseases (ILD) constitute a heterogeneous group of conditions exhibiting inflammation and scarring of the lung parenchyma. Pathological changes are spatially heterogeneous with varying degrees of acute inflammation and fibrosis. The ILDs have varying aetiologies and natural history. Typically, idiopathic pulmonary fibrosis (IPF), the most common ILD, has a chronic progressive phenotype, whereas other sub-types such as drug-induced ILD (DI-ILD) [1] and hypersensitivity pneumonitis (HP) [2] may reverse following withdrawal of the trigger. Diagnosis of ILDs remains a challenge, with a requirement for a multi-disciplinary assessment combining clinical history, immune profiling, lung physiology, computed tomography (CT), and lung biopsy [3]. It is important to accurately classify a subject's ILD subtype as this has an impact on the prognosis as well as the choice of the most effective treatment for the patient, e.g., antifibrotics in IPF [4] and immunosuppressants for other subtypes [1]. Thus, there is a need for improved biomarkers for precise diagnosis and monitoring of disease progression and treatment efficacy. Pulmonary function tests (PFTs) lack disease specificity as they measure the global function of the lungs only [5] and cannot interrogate regional change in ILD, unlike imaging biomarkers, which provide regional information [6]. Numerous observational studies have reported cohort predictors of ILD progression and/or mortality [7,8]; however, accurate prognosis for individual ILD patients remains a challenge. Most imaging biomarker studies in ILD have focused on IPF [9] in small numbers of subjects without independent validation [3].

Where repeated assessments are required, it is desirable to avoid ionising radiation, and risks from imaging contrast agents should be minimised. MRI biomarkers therefore are of particular interest, particularly when benign inhaled gases such as oxygen or hyperpolarised 129-xenon (^{129}Xe) are used to provide additional structural and physiological information [10–15]. Hyperpolarised ^{129}Xe MRI exploits the signal enhancement available following spin exchange optical pumping to allow for the direct visualization of inhaled gases and ventilation at high resolution [16]. In this work, only ^{129}Xe ventilation MRI has been considered, and more complex techniques based on spectroscopy of dissolved ^{129}Xe [9,16] or diffusion-weighted MRI [15] were not included.

The technology to produce and visualise hyperpolarised gases in clinical settings is currently limited to a few specialised centres [17], as hyperpolarised ^{129}Xe is categorised as an investigational medicinal product and the expense of the added equipment and personnel required limits its widespread use. For this reason, alternative methodologies to image ventilation are of interest. One candidate is oxygen enhanced MRI (OE-MRI), which exploits the effect of molecular oxygen on lung tissue water in conventional proton MRI. Pure oxygen and medical air are widely available in hospital settings, and their delivery can be reliably achieved with standard medical equipment [18].

OE-MRI permits quantification of change in concentration of dissolved oxygen in lung tissues induced by inhaling changed concentrations of O_2 [19], and has previously been deployed in other lung diseases [20,21]. OE-MRI is usually paired with a measurement of native T_1 in the parenchyma, itself a promising imaging biomarker of focal lung disease [22,23]. There is still little published information on the performance of such MR biomarkers in ILD, their temporal evolution, and correlations between the different MR biomarkers and conventional pulmonary function tests.

In this study we aimed: firstly, to compare imaging biomarkers derived from ^1H T_1 mapping, dynamic OE-MRI and hyperpolarised ^{129}Xe ventilation MRI with standard lung physiological measurements in ILD

patients in comparison to healthy volunteers (HV); secondly, to compare these MRI biomarkers between ILD subtypes; and thirdly, to assess longitudinal changes in these MRI biomarkers.

2. Materials and methods

2.1. Participants

The study was carried out as part of a programme to validate imaging biomarkers of drug safety [24]. It was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the local research ethics committee (United Kingdom North West -Preston Research Ethics Committee, REC Ref 17/NW/0631, IRAS number: 232495). The study investigated several imaging biomarkers intended to probe lung morphology, perfusion, and ventilation. This report includes only the subgroup of patients in whom OE-MRI and ^{129}Xe ventilation MRI was performed.

Patients with a diagnosis of ILD were recruited and assigned to one of four ILD subtypes: suspected DI-ILD, connective tissue disease related-ILD (CTD-ILD), IPF or HP.

The diagnosis of the ILD subtype was established in ILD multidisciplinary team (MDT) meetings involving respiratory physicians, thoracic radiologists, and pathologists, the gold standard for the diagnosis of ILD since the publication of the ATS/ERS IIP classification in 2002 [25].

Potential subjects were identified by respiratory physicians during ILD MDT meetings where patients' cases were discussed as part of routine clinical care. Current diagnostic investigations in ILD mainly consist of HRCT and PFTs [25]. It should be noted that often a definitive diagnosis cannot be achieved by the MDT, but instead a "working diagnosis" of high probability can be reached by combining the key information available to increase or decrease the diagnostic probability of a specific ILD subtype [26]. As this was an observational trial, recruited patients followed the usual standard of care, but treatment regime was noted.

Exclusion criteria were: significant pre-existing cardio-pulmonary disease, radiotherapy to the lung fields within 6 months, any features of any malignancy involving the lungs, evidence of lower respiratory infection, estimated survival <6 months and any contraindication for MR imaging.

Patients were recruited, gave written informed consent, and underwent a clinical assessment, lung function testing and MRI at visit 1. Patients were recalled for a follow up visit after 6 weeks (if diagnosed with suspected DI-ILD or HP) or 6 months (if diagnosed with IPF or CTD-ILD). The follow up schedules were tailored to enable the capture of change at the most appropriate time points for each disease group, as IPF patients typically show a slower progressive decline while DI-ILD and HP often either rapidly declines or improves with treatment. Additionally, ten healthy volunteers (HV) were also recruited under ethical approval provided by the UK national research ethics committee (REC Ref 12/NE/0355), with all volunteers giving written informed consent to undergo pulmonary function testing and MRI at baseline only.

2.2. Pulmonary function tests

Patients underwent pulmonary function testing prior to MRI scanning, performed to international standards [27] under the supervision of a trained respiratory physiologist. Spirometry was performed to assess the forced expiratory volume in 1 s (FEV₁) and forced vital capacity (FVC). Gas transfer testing assessed the transfer factor (TL_{CO}) and coefficient (K_{CO}) of the lungs for carbon monoxide [28,29]. All values are reported as % predicted using the Global Lung Function Initiative (GLI)

Table 1

Imaging parameters for ^{129}Xe and OE acquisitions. SPGR: spoiled gradient echo, SSFP: steady state free precession, IR-TFE: inversion recovery turbo spin echo, TE: echo time, TR: repetition time.

Metric	^1H (SPGR)	^{129}Xe ventilation (SSFP)	T_1 Mapping (IR-TFE)	Dynamic OE (IR-TFE)
Acquisition matrix	100×100	100×80	96×96	96×96
Pixel size (mm ²)	4×4	4×4	4.2×4.2	4.2×4.2
Slice thickness (mm)	5	10	10	10
Flip angle (degrees)	5	10	5	5
TE/TR (ms)	0.6/1.9	2.2/6.7	0.4/1.5	0.4/1.5
BW (kHz)	± 83.3	± 8.0	± 31.25	± 31.25

2012 reference eqs. [30].

2.3. Imaging

All imaging was carried out in the coronal plane on a 1.5 T whole body system (GE HDx, GE Healthcare, Milwaukee, WI): **Table 1** provides details on the sequences used.

2.3.1. Hyperpolarised ^{129}Xe imaging

Hyperpolarised ventilation ^{129}Xe imaging was performed using a flexible quadrature transmit/receive quadrature coil (Clinical MR Solutions, Brookfield, Wisconsin, USA). ^{129}Xe was polarised under regulatory licence to $\sim 30\%$ using an in-house spin exchange optical pumping polariser capable of generating 500 ml doses in < 15 min [31]. ^{129}Xe images were acquired at a breath-hold of functional residual capacity plus 1 l of gas mixture (FRC + 1 l, 500 ml ^{129}Xe , 500 ml N_2) with a 3D balanced steady-state free precession (bSSFP) sequence with a 10 mm slice thickness and pixel size of $4 \text{ mm} \times 4 \text{ mm}$. Prior to the acquisition of the ^{129}Xe images, a ^1H structural 3D spoiled gradient echo (SPGR) image was acquired at FRC + 1 l utilising a 1 l bag of N_2 . The ^1H structural image had the same in plane spatial resolution, but a slice thickness of 5 mm compared to 10 mm for the ^{129}Xe image to allow for an affine co-registration and the estimation of the percentage lung ventilated volume (Xe-VVF) [32]. To ensure all subjects were able to complete the breathing manoeuvre, appropriate training took place prior to imaging.

2.3.2. Inversion recovery T_1 measurement and dynamic oxygen-enhanced imaging

Following completion of ^{129}Xe imaging, subjects were repositioned in an 8-element ^1H chest receiver coil and were fitted with a disposable non-rebreathing mask to allow for medical air and oxygen delivery. A free-breathing protocol based on an inversion-prepared centric ordered single shot 3D-turbo field echo (IR-TFE) sequence was used [33] with 10 mm slice thickness and $4.2 \text{ mm} \times 4.2 \text{ mm}$ spatial resolution. A baseline T_1 map was calculated from 6 acquisitions with variable inversion time (TI) (40, 100, 300, 1100, 2000 and 5000 ms). Five volumes were acquired for each TI, to capture different stages of the respiratory cycle. A dynamic OE acquisition followed, lasting 15 min (TI = 1100 ms) with a temporal resolution of 10 s, during which gas was delivered at 15 l/min and switched from medical air to 100% O_2 at minute 2, and back to air at minute 10 [34].

2.4. Image analysis

2.4.1. ^{129}Xe image analysis

^1H structural images were co-registered to the same spatial domain as the ^{129}Xe ventilation image and segmented semi-automatically using spatial fuzzy c-means thresholding and manual editing [31]. Xe-VVF

was calculated by dividing the ventilated volume (from the ventilation image) by the thoracic cavity volume (from the ^1H structural image). Additionally, the median and interquartile range (IQR) of the coefficient of variation (CV) of ventilated signal intensity was calculated [35,36], with the IQR of the whole lung CV being referred to as the xenon ventilation heterogeneity index (Xe-VH_I). Briefly, for CV calculation the ^{129}Xe images were subsampled in-plane by 50% and a 3×3 sliding window used to calculate voxel-wise CV, incorporating only voxels identified as ventilated (from the ventilated volume mask).

2.4.2. Inversion recovery T_1 and dynamic oxygen-enhanced imaging analysis

All OE-MRI images were co-registered using ANTS [37] to a reference image representing expiration. Baseline T_1 was calculated by fitting the inversion recovery data as previously described [34].

The lung cavity was semi-automatically segmented from the reference image using a region growing algorithm from manually defined points. Lung volume changes during the dynamic acquisition were estimated from the mask and the deformation field extracted from the registration. The registration was assessed by extracting the apparent diaphragm displacement from the dynamic images after motion-correction: any frame presenting an apparent post-correction displacement > 1 pixel was excluded from further analysis.

The dynamic signal at each pixel in the lung parenchyma was modelled by sum of two signals: (1) a component dependent on lung volume change, describing the local variation in local proton density during the respiratory cycle and (2) a piecewise mono-exponential recovery function in the time domain, modelling the local increase in T_1 -weighted MR signal due to an increase in concentration of dissolved molecular oxygen after gas switching.

To account for the first element, a first-degree polynomial fit between the log-transformed pixelwise MR signal and the log-transformed whole lung volume changes was calculated and subtracted from the original signal. The oxygen enhancement was then derived by the change in signal intensity between the median values on medical air and the median values of the last ten frames on 100% O_2 . This signal change was then converted to the change in R_1 [38], and then into a change of partial pressure of oxygen ($\Delta p\text{O}_2$), using the longitudinal relaxivity in water ($r_{1\text{O}_2}$) of $2.49 \times 10^{-4} \text{ mmHg}$ [39].

In line with the ^{129}Xe analysis, the median value of the coefficient of variation of the $\Delta p\text{O}_2$ map (median CV $\Delta p\text{O}_2$) was extracted by a 3×3 2D kernel. The interquartile range of this map was also calculated, as the oxygen enhanced ventilation heterogeneity index (OE-VH_I).

The oxygen wash in time (τ_{up}) was estimated by fitting the signal with a piecewise mono-exponential curve. When the Akaike information criterion (AIC) favoured the latter fitting over a constant function, the pixel was considered as ventilated, which allowed the calculation of the oxygen enhanced ventilated volume fraction (OE-VVF). The OE-VVF was applied to the τ_{up} map as a mask to exclude pixels with no detectable oxygen enhancement.

2.5. Statistics

The five ^1H MRI biomarkers (T_1 , $\Delta p\text{O}_2$, τ_{up} , OE-VH_I and OE-VVF) and the two ^{129}Xe ventilation biomarkers (Xe-VVF and Xe-VH_I), were compared with the spirometry (FEV₁%, FVC%), and the gas transfer biomarker TL_{CO}%. To evaluate differences in biomarkers at visit 1 among the ILD subgroups and the healthy volunteers, ANOVA or Kruskal-Wallis rank tests followed by post hoc test with Bonferroni or Dunn correction for multiple comparisons were carried out (depending on the result of the Shapiro-Wilk normality test). The level of significance was set at $p = 0.05$ for these tests after multiple correction.

Also, the considered population data at visit 1 was divided into three groups: healthy volunteers, ILD subject with TL_{CO}% $> 75\%$ (High TL_{CO}%) and ILD subject with TL_{CO}% $\leq 75\%$ (Low TL_{CO}%). A similar analysis to the one just described was carried out to determine if any




Fig. 1. Comparison of obtained images from ^{129}Xe ventilation (first row, with CT) and T1 and OE-MRI (second row) in a single slice for a subject diagnosed with IPF (FEV1% 85.8, FVC% 66.3, TLCO% 26.6, KCO% 44).




Fig. 2. Front to back slice by slice comparison of ^{129}Xe images (first row) and OE-MRI $\Delta p\text{O}_2$ enhancement (second row) and oxygen wash in rate (third row) a subject affected by Hypersensitive Pneumonitis. Ventilation appears to be fairly homogeneous with both modalities. The main ventilation defect visible on the ^{129}Xe images is located in the upper right lobe and indicated by an asterisk. The same area presents normal oxygen enhancement levels but high oxygen wash-in rate. Apparent artefacts are visible close to the heart in the left lung in OE-MRI images [19].

imaging biomarker could separate HV from both High TLCO% and Low TLCO% groups.

To assess the relationships between imaging biomarkers, Pearson correlations were carried out. Pearson correlations were also carried out between each of the imaging biomarkers and PFTs and age/gender, both at visit 1 and (separately) for the between visits change. The level of significance was set at $p = 0.01$ for these tests. When at least one significant correlation was found, the best multilinear regression model was identified as having had the imaging biomarker as an independent parameter, the PFTs and age as a continuous covariate and sex and disease status (HV, IPF, DI-ILD, CTD-ILD, HP) as categorical variables, using a stepwise method guided by a decreasing AIC. The results of the multivariate models are presented as the coefficient β and its 95% confidence interval and R^2 , the percentage of variation in the response

that is explained by the model.

To assess the change of PFT between visits in the whole population, and in each of the ILD subgroups, a one sample t -test or Wilcoxon signed rank test was carried out. The level of significance was set at $p = 0.01$ for these tests. No correction for multiple comparisons was applied.

Moreover, subjects were divided in two groups depending on whether they received a pharmacological treatment for ILD during the study. The change in biomarker between visits was compared between the two groups with a two-tailed t -test or a Wilcoxon signed rank test depending on the result of the Shapiro normality test. The level of significance was set at $p = 0.01$ for these tests. No correction for multiple comparisons was applied. All statistical analysis were run using Python libraries SciPy (version 1.6.0) and statsmodels (version 0.12.0).




Fig. 3. Front to back slice by slice comparison of ¹²⁹Xe images (first row) and OE-MRI ΔpO₂ enhancement (second row) and oxygen wash in rate (third row) a subject affected by idiopathic pulmonary fibrosis. Significant differences in contrast between modalities are clearly visible, but some commonality in ventilation defects are also evident (arrow, asterisk and plus signs).




Fig. 4. Flow chart representing patient recruitment during the study.

3. Results

Fig. 1 shows one representative slice from all considered biomarker maps, ¹²⁹Xe biomarker, CT, and OE-MRI for an IPF subject. Figs. 2 and 3 show a comparison of anterior-posterior slices from the ¹²⁹Xe volumetric acquisition and OE-MRI enhancement map and wash-in rate of a subject with HP and a patient with IPF. A clear gradient in ¹²⁹Xe spin density front-to-back is clearly visible in ¹²⁹Xe ventilation images. This gradient seems reversed in ΔpO₂ images, with posterior images enhancing less than anterior ones. In Fig. 2 ventilation is mostly uniform, but a ventilation defect visible on ¹²⁹Xe images is visible in the upper right lung and corresponds to normal ΔpO₂ enhancement but high τ_{wp}. Apparent artefacts are visible in the left lung, close to the heart, in OE-MRI images. In Fig. 3, significant differences in contrast in between modalities are clearly visible, but some commonality in ventilation defects are also evident (arrow, asterisk and plus signs).

3.1. Population characteristics

Fig. 4 summarises in a flow chart the patient recruitment in the study. Forty-one ILD patients were recruited (14 IPF, 11 HP, 11 DI-ILD and 5 CTD-ILD) and successfully imaged at visit 1. Thirty-six complete datasets of ILD patients imaged at visit 1 were analysed (12 IPF, 10 HP, 11 DI-ILD and 3 CTD-ILD). Five subjects were not analysed; one subject due to the dynamic OE-MRI protocol not being fully performed and four subjects OE-MRI datasets were excluded due to absent or weak O₂ enhancement in the blood pool as measured in the aorta, which indicated issues with the gas delivery during scanning.

Thirty-four ILD patients attended and completed visit 2 (11 IPF, 8 HP, 10 DIILD, 5 CTD-ILD). Of the seven patients who failed to attend, three subjects died between visit 1 and visit 2, two withdrew from the study, one was lost at follow up and one could not be scanned in the appropriate time window due to MR hardware issues. One of the thirty-four acquisitions could not be analysed due to inconsistent field of view prescription among the OE acquisitions. No incidental findings were reported in the study population.

Table 2

Summary statistics of age, lung test and image biomarkers at visit 1 (v1) and their change between visit 1 and visit 2 for all subjects involved in the study (v2-v1). IPF: idiopathic pulmonary fibrosis, DIILD: drug induced interstitial lung disease, CTD-ILD: connective tissue disease-associated interstitial lung disease, HP: hypersensitivity pneumonitis, HV: healthy volunteers, FEV₁: forced expiratory volume in one second, FVC: forced vital capacity, TL_{CO}: transfer capacity of the lung for the uptake of carbon monoxide, K_{CO}: carbon monoxide transfer coefficient, Xe-VVF: percentage of ventilated volume as calculated by ¹²⁹Xe MRI, Xe-VH_I: ventilation heterogeneity index, ΔpO₂: change in oxygen partial pressure, τ_{up}: wash-in rate of oxygen, OE-VVF: ventilated volume as calculated by oxygen-enhanced MRI, OE-VH_I: ventilation heterogeneity index as calculated by oxygen-enhanced MRI, T₁: inversion recovery T₁, v1: visit 1, (v2-v1) difference between visit 2 and visit 1.

	DIILD	IPF	HP	CTD-ILD	HV
	Visit 1 n = 11	Visit 1 n = 14	Visit 1 n = 11	Visit 1 n = 5	Visit 1 n = 9
	Visit 2 n = 9	Visit 2 n = 9	Visit 2 n = 7	Visit 2 n = 5	
Male/female v1	8/3	13/1	3/8	3/2	6/3
Age [y]	66.4 ± 9.6	71.9 ± 7.18	61.5 ± 12.5	58.5 ± 10.9	49.4 ± 17.4
FEV ₁ % v1	84.2 ± 24.0	93.5 ± 23.5	74.4 ± 24.4	89.0 ± 11.0	95.2 ± 10.7
FEV ₁ % (v2-v1)	-2.4 ± 9.3	-2.2 ± 7.3	2.6 ± 4.2	-0.9 ± 5.5	
FVC% v1	82.9 ± 24.4	92.8 ± 26.4	74.1 ± 25.2	88.1 ± 12.7	101.4 ± 9.6
FVC% (v2-v1)	-2.2 ± 8.4	-3.8 ± 8.3	3.2 ± 4.8	-0.6 ± 5.4	
TL _{CO} % v1	56.0 ± 21.6	55.3 ± 18.6	56.4 ± 18.4	57.4 ± 19.6	97.6 ± 8.6
TL _{CO} % (v2-v1)	-1.1 ± 9.5	-5.4 ± 0.0	-3.6 ± 12.7	4.2 ± 4.6	
K _{CO} % v1	72.0 ± 21.8	69.8 ± 19.1	81.9 ± 22.1	72.0 ± 12.7	105.7 ± 13.5
K _{CO} % (v2-v1)	-2.21 ± 8.0	-5.2 ± 8.3	-12.3 ± 20.6	1.5 ± 5.7	
Xe-VVF v1	90.1 ± 7.4	88.1 ± 6.5	92.6 ± 4.0	91.0 ± 4.8	97.4 ± 2.6
Xe-VVF (v2-v1)	1.2 ± 5.3	-0.22 ± 6.2	-1.2 ± 5.1	0.58 ± 8.3	
Xe-VH _I v1	0.12 ± 0.03	0.13 ± 0.01	0.11 ± 0.03	0.11 ± 0.01	0.09 ± 0.01
Xe-VH _I (v2-v1)	0.00 ± 0.02	-0.00 ± 0.01	0.00 ± 0.1	0.00 ± 0.02	
Δ pO ₂ [mmHg] v1	172.3 ± 48.2	141.6 ± 43.9	187.1 ± 41.9	244.6 ± 18.6	186.8 ± 48.4
Δ pO ₂ [mmHg] (v2-v1)	-20.8 ± 56.4	33.5 ± 69.9	-0.6 ± 56.9	-64.4 ± 7.9	
τ _{up} [s] v1	60.2 ± 26.6	47.4 ± 19.1	44.9 ± 24.1	58.5 ± 41.6	38.8 ± 13.4
τ _{up} [s] (v2-v1)	-2.5 ± 35.8	4.5 ± 35.0	-22.9 ± 18.1	-19.7 ± 33.3	
OE-VVF v1	74.6 ± 11.8	69.2 ± 13.6	82.4 ± 9.9	88.6 ± 3.6	80.8 ± 9.8
OE-VVF (v2-v1)	-6.5 ± 10.4	7.5 ± 8.5	-0.0 ± 0.1	-10.9 ± 7.6	
OE-VH _I v1	0.35 ± 0.10	0.40 ± 0.01	0.26 ± 0.12	0.22 ± 0.03	0.27 ± 0.13
OE-VH _I (v2-v1)	0.06 ± 1.0	-0.07 ± 0.06	3.7 ± 6.5	0.13 ± 0.1	
T ₁ [ms] v1	1095.8 ± 55.9	1135.4 ± 47.4	1097.4 ± 78.3	1072.6 ± 41.8	1180.8 ± 95.5
T ₁ [ms] (v2-v1)	40.3 ± 104.5	15.7 ± 89.3	38.9 ± 63.7	75.4 ± 110.7	

A total of twenty-nine ILD patients (nine IPF, ten HP, seven DILD, three CTD-ILD) completed both visits and had analysable OE-MRI datasets. One HV was excluded from the analysis due to a radiological incidental finding, and the remaining nine HV were analysed. Table 2 summarises biomarker results obtained at visit 1 and the

change between visits (visit 2 – visit 1).

Regarding pharmacological treatment, in the IPF group, four subjects were treated with an antifibrotic (Nintedanib), while the remaining subjects were not under pharmacological treatment. Among the subjects diagnosed with HP, all were treated with a corticosteroid (prednisone); in addition to this, one HP patient also received Azathioprine (AZA) and four patients also received Mycophenolate Mofetil (MMF). In the CTD-ILD group, one subject received no pharmacological treatment during the study, two were on a corticosteroid plus AZA and two on a corticosteroid plus MMF. Among subjects diagnosed with DI-ILD, six received a corticosteroid, while five did not receive drugs for the condition as their management plan involved withdrawal of the causative drug only. Starting, stopping and length of treatment also varied widely during the study.

3.2. PFTs and imaging biomarkers at visit 1

No difference was found in FEV₁% and FVC% between HV and any ILD subgroups. HV had higher TL_{CO}% ($p < 0.001$) than all ILD groups, while HV had statistically higher K_{CO}% than IPF ($p < 0.0001$), DI-ILD ($p = 0.01$) and CTD-ILD ($p = 0.01$), but not HP ($p = 0.12$). There were no significant differences between ILD subgroups for these biomarkers (Fig. 5). The subgroup considered differed in age: HV (HV: 49.4 ± 17.4 y) were significantly younger than the IPF (IPF: 71.9 ± 7.18 y, $p = 0.004$). IPF patients were also older than CTD-ILD patients (58.5 ± 10.9 y, $p = 0.04$) (Table 2).

Fig. 6 presents the boxplot of the considered ¹²⁹Xe biomarkers and Fig. 7 presents the boxplot of the considered OE-MRI biomarkers, divided by ILD subgroups. Regarding ¹²⁹Xe biomarkers, the ventilation volume fraction was lower in all ILD groups than in HV (Xe-VVF: HV mean ± std. 97.4 ± 2.6, CTD-ILD: 91.0 ± 4.8, $p = 0.017$, DI-ILD 90.1 ± 7.4 $p = 0.003$, HP 92.6 ± 3.8 $p = 0.013$, IPF 88.1 ± 6.3 $p < 0.001$), but this was not replicated with the OE ventilation volume fraction. As for PFTs, when averaged across the lung, the OE-MRI biomarkers generally failed to distinguish the ILD subgroups, with the exception that ΔpO₂ was higher in CTD-ILD than in IPF ($p = 0.016$).

There were however significant differences in ventilation heterogeneity between ILD groups. Xe-VH_I was lower in HV than in IPF ($p < 0.001$). Xe-VH_I was also lower in the CTD-ILD group than in IPF ($p < 0.001$), and lower in HP than in IPF ($p = 0.042$).

If visit 1 subjects are divided between HV, High TLCO% and Low TLCO% groups, Xe-VVF was higher in HV than in both ILD groups (HV 97.38 ± 2.64, High TLCO%: 94.11 ± 5.317, Low TLCO% 90.25 ± 6.38%, HV vs High $p = 0.002$, HV vs Low, $p < 0.001$).

Xe-VH_I was significantly lower in HV (0.095 ± 0.013) than in Low TLCO% (0.123 ± 0.02, $p = 0.006$), but not significantly different than in the High TLCO% (0.105 ± 0.021).

Similarly, T₁ is higher in HV (1180.7 ± 95.5 ms) than in Low TLCO% (1103.4 ± 63.2 ms, $p = 0.02$), but not than in High TLCO% (1157.68 ± 83 ms). τ_{up} was lower in HV (38.77 ± 12.68 s) than in HighTLCO% (49.32 ± 20.18 s, $p = 0.03$), but not significantly different than in Low TLCO% (48.8 ± 24.4 s).

Table 3 shows the Pearson correlation coefficients between imaging biomarkers at visit 1. No significant correlation was found between Xe-VVF and OE-VVF, nor between Xe-VH_I and OE-VH_I. There was a weak but significant correlation between τ_{up} and VVF ($R = -0.38$, $p = 0.009$).

Multilinear regression models applied to the whole considered population demonstrated that age ($\beta = -0.2$; 95%CI = -0.33, -0.11; $p < 0.001$) and TL_{CO} ($\beta = 0.07$; 95%CI = 0.005, 0.136; $p = 0.035$) were significantly correlated with Xe-VVF ($R^2 = 0.39$).

Age ($\beta = 0.0007$; 95%CI = 10⁻⁴, 10⁻³; $p = 0.001$), TL_{CO} ($\beta = -0.0003$, 95%CI = 10⁻⁴, 10⁻³; $p = 0.013$) and gender ($\beta = 0.019$; 95%CI = 0.009, 0.031; $p = 0.001$) were significantly correlated with Xe-VH_I ($R^2 = 0.53$).

Age ($\beta = -2.32$; 95%CI = -3.85, -0.79; $p = 0.004$), FVC% ($\beta = 0.97$, 95%CI = 0.13, 1.81; $p = 0.025$), and IPF diagnosis ($\beta = 33.2$; 95%CI =




Fig. 5. Boxplot of pulmonary function tests results at visit 1 in the studied population, split in ILD subgroups. Data are reported as % predicted. (*) $p < 0.05$, (***) $p < 0.001$ FEV₁: forced expiratory volume in one second, FVC: forced vital capacity, TLC₀: transfer capacity of the lung for the uptake of carbon monoxide, K_{CO}: carbon monoxide transfer coefficient,

–14.53, 80.99; $p = 0.168$) were correlated with T_1 ($R^2 = 0.24$). No other associations were observed. The full table of Pearson correlation coefficients is available in the Supplementary Materials (Table 1).

3.3. Changes between visits

Boxplots representing the longitudinal changes in the considered biomarkers are visualised in the Supplementary Materials Figs. 1–3. Regarding longitudinal changes, no statistically significant changes were found in individual ILD subgroups or in the overall ILD population.

If the population is divided between subjects who received pharmacological treatment for ILD during the study, and subjects who did not, no significant difference in the biomarker changes were found between the two groups.

3.4. Multilinear models – imaging biomarkers (visit 2 – visit1)

Only age at visit 1 was a significant predictor of the change in VVF between visits ($R^2 = 0.145$; $\beta = 0.2$; 95%CI = 0.026, 0.44; $p = 0.029$). Multilinear models indicated that change of FEV₁% was significantly correlated with the change in T_1 between visits ($R^2 = 0.138$, $\beta = -0.47$; 95%CI = -9.33, -0.157; $p = 0.043$) but no further associations with

MRI biomarkers were observed. The full table of Pearson correlation coefficients is available in the Supplementary Materials (Table 2).

4. Discussion

Despite the complexity of the imaging employed in the study, only 2 subjects withdrew, demonstrating the feasibility of multi-sequence MR acquisition in ILD, also in patients with severely deteriorated lung function. Issues with oxygen delivery during scanning were detected – methods to identify when gas delivery is failing during scanning may be helpful in the future to improve data quality.

In this study, none of the global measurements (PFT, average T_1 , or any of the global OE-MRI or ¹²⁹Xe ventilation biomarkers) differentiated between ILD subtypes, although biomarkers of focal variation (OE-VH_l and Xe-VH_l) may show differences in ventilation heterogeneity between ILD subtypes. The importance of accurately and quickly classifying a subject’s ILD subtype comes from the impact on the prognosis as well as the choice of the most effective treatment for the patient (e.g., immunosuppression versus antifibrotic therapy). The results from this study suggest that ventilation-only biomarkers are not suitable for this specific objective, nor to track the longitudinal changes. In fact, the longitudinal change in the imaging biomarkers did not correlate with PFT changes




Fig. 6. Boxplot of pulmonary ^{129}Xe biomarkers at visit 1 in the studied population, split in ILD subgroups. (*) $p < 0.05$, (**) $p < 0.01$, (***) $p < 0.001$. % ^{129}Xe -VVF: percentage of ventilated volume as calculated by ^{129}Xe MRI, Xe-VH_i: ventilation heterogeneity index as calculated by ^{129}Xe .

between the two timepoints.

The significant correlation between τ_{up} and Xe-VVF suggests that areas of the lung not reached by ^{129}Xe during the breath-hold experiment may be reached by oxygen at a slower rate during the significantly longer free breathing OE-MRI experiment. This would also be consistent with the observation that, unlike Xe-VVF, the fraction of lung apparently ventilated by oxygen (OE-VVF) did not differentiate between groups.

The only imaging biomarker that could separate the healthy volunteers and both the high and low TLCO% groups was Xe-VVF, which indicates that a limited but progressive loss of ventilated volume may occur as disease progresses.

The ILD patients recruited at baseline had on average near normal FVC% and FEV₁%, but similar low TLCO%; it is perhaps therefore unsurprising that functional imaging contrasts that are dominated by ventilation were unable to differentiate these groups [30]. Perhaps more surprisingly, as noted above, ventilated volume fractions did not correlate between OE-MRI and ^{129}Xe -MRI. In addition to the differences in the time scales over which the measurements are performed, this lack of correlation is possibly because OE-MRI measures signal enhancement in the parenchyma and blood in the lungs following oxygen ventilation, and is therefore best considered as creating contrast weighted by both ventilation and perfusion, while ventilation ^{129}Xe -MRI directly measures ventilation in the airways and the alveoli; alternatively, it may simply reflect the relative variability and small numbers in this work.

The OE-VVF obtained in this work is relatively low also in healthy volunteers ($80.8 \pm 9.8\%$). Lack of enhancement is expected in bronchi and arteries in this imaging method, therefore reducing the achievable VVF to $<100\%$. It is also possible that movement artefacts from breathing, the cardiac cycle and bulk movements may contribute to decreased OE-VVF.

Also, while both OE-MRI and ^{129}Xe -MRI suggested more heterogeneous ventilation in DI-ILD and IPF, ventilation heterogeneity index measurements failed to correlate between the two modalities, potentially for the same underlying reasons.

Correlation between Xe-VVF obtained with ^3He imaging and OE-VVF has been seen in a cystic fibrosis study [40] which did not investigate oxygen wash-in time. The lung pathology typical of CF is characterised by airway obstruction, leading to markedly decreased FEV₁ and FVC, markedly different from the fibrotic pathology present in ILD. Further studies are necessary to investigate the apparent distribution of different

gases as visualised by MR imaging in an array of pulmonary diseases.

It is well known that ^{129}Xe ventilation biomarkers correlate strongly with age [41]. When age is considered in a multilinear model, Xe-VVF and VH_i are significantly correlated with TLCO at visit 1. This result also indicates that reduction in ventilation volume and increase in ventilation heterogeneity in subjects with higher thickening of the alveolar-capillary membrane.

Sex is also independently correlated with VH_i, with female subjects presenting more uniformly ventilated lungs than male. Females are known to have a significant survival advantage in IPF [7], and this may be an additional indication of the mechanism behind this.

Lung T₁ correlated negatively with age, but sex was not found to predict T₁ in this population composed mostly of ILD patients. This can be compared with the findings of Kindval et al. [42] who found a negative correlation between lung T₁ and age in female healthy volunteers. Lung T₁ also linearly correlated with FVC% when age is considered, and IPF patients present higher lung T₁ than the rest of the population. Stadler et al found that fibrotic patients in inspiration presented higher T₁ than emphysema patients [43], and this may explain the latter finding since the IPF population tends to present more as a fibrotic phenotype than other ILD types, and the acquisition was done in free breathing, so with inflated lungs.

The relationships found at visit 1 between imaging biomarkers and PFTs were mostly lost when considering short-term (6 weeks or 6 months) longitudinal changes. Among the ^{129}Xe ventilation biomarkers, the ventilated volume Xe-VVF change was significantly correlated only with age. Lung T₁ changes were negatively correlated with the change in FEV₁%. Since the change in PFTs between visits was small, this may explain the lack of correlation between imaging biomarkers and PFTs.

A limitation of this work is that, as a sub study, it was not adequately powered to address every question discussed here. Furthermore, the subjects were not uniformly distributed across the disease groups, reflecting challenges with the recruitment of rarer ILD variants. It is therefore possible that a larger study would uncover additional relationships. Subacute hypersensitivity pneumonitis is characterised by air trapping [44], so this subgroup may have been expected to have lower ventilated volume fractions than other ILD subtypes, but this was not found in this population. Also, the age differences between healthy volunteers and the IPF group is a potential issue. Potential further development within the field may also lead to a growing understanding




Fig. 7. Boxplot of pulmonary proton MR biomarkers at visit 1 in the studied population, split in ILD subgroups. (*) $p < 0.05$, (**) $p < 0.01$. ΔpO_2 : change in oxygen partial pressure, τ_{up} : wash-in rate of oxygen, OE-VVF: percentage of ventilated volume as calculated by oxygen-enhanced MRI, OE-VH_i: ventilation heterogeneity index as calculated by oxygen-enhanced MRI, T₁: inversion recovery T₁.

Table 3

Pearson correlation R between ventilation ^{129}Xe and OE-MRI biomarkers at visit 1. *P* values are indicated when $p < 0.05$. Xe-VVF: percentage of ventilated volume as calculated by ^{129}Xe MRI; Xe-VH_i: ventilation heterogeneity index as calculated by ^{129}Xe MRI; Xe-VH_e: ventilation heterogeneity index as calculated by ^{129}Xe MRI; $\Delta p\text{O}_2$: change in oxygen partial pressure; τ_{up} : wash-in rate of oxygen, OE-VVF: percentage of ventilated volume as calculated by oxygen-enhanced MRI, OE-VH_i: ventilation heterogeneity index as calculated by oxygen-enhanced MRI, T₁: proton longitudinal relaxation time.

	Xe-VVF	Xe-VH _i
T ₁ [ms]	0.15	-0.34 ($p = 0.044$)
$\Delta p\text{O}_2$ [mmHg]	0.02	-0.05
OE-VH _i	-0.02	0.22
τ_{up} [s]	-0.38 ($p = 0.009$)	0.34 ($p = 0.021$)
OE-VVF	0.07	-0.23

of the imaging techniques and further insights into disease pathology, physiology and progression may develop over time with increasing experience and patient numbers.

Another limitation regards the observational nature of the study. Subjects received varied treatment regimens before and after recruitment, due to the different origin of ILD and a wide range of disease severity. Also, the timing of the baseline study visits in relation to the management of non-IPF subjects varied between the two centres. It is possible that the variation in the patient management in the study could have influenced the longitudinal changes in the biomarkers and a more standardised approach may have resulted in different outcomes. Therefore, the failures of the imaging biomarkers in distinguishing longitudinal changes between the group receiving or not pharmacological treatment must be interpreted cautiously.

Another limitation of our work is its focus on imaging techniques that are centred around ventilation imaging. There exist alternative techniques, such as spectroscopy and diffusion-weighted ^{129}Xe MRI [9,14,45] or ^1H perfusion MRI [46], which are capable of probing other lung properties such as gas exchange, lung microstructure and blood perfusion. Such measurements provide a promising alternative class of imaging biomarkers for ILD.

5. Conclusions

In conclusion, none of the global measurements investigated in this study were able to differentiate between ILD subtypes, suggesting that ventilation-only biomarkers are not indicated for this task. Limited but progressive loss of ventilated volume as measured by ^{129}Xe -MRI may be present as disease progresses, but no ventilation biomarker investigated in this study is a good candidate for monitoring longitudinal changes in ILD. ^{129}Xe ventilation biomarkers correlated strongly with age and TLCO at visit 1, but the correlations were mostly lost when considering short-term (6 weeks or 6 months) longitudinal changes.

Both OE-MRI and ^{129}Xe MRI revealed more spatially heterogeneous ventilation in DI-ILD and IPF.

CRediT authorship contribution statement

Marta Tibiletti: Software, Visualization, Formal analysis, Writing – original draft, Writing – review & editing. **James A. Eaden:** Investigation, Data curation, Writing – review & editing. **Josephine H. Naish:** Software, Supervision, Writing – review & editing. **Paul J.C. Hughes:** Software, Validation, Visualization, Writing – review & editing. **John C. Waterton:** Funding acquisition, Conceptualization, Writing – review & editing. **Matthew J. Heaton:** Software, Validation, Data curation, Writing – review & editing. **Nazia Chaudhuri:** Investigation, Writing – review & editing. **Sarah Skeoch:** Conceptualization, Methodology, Investigation, Writing – review & editing. **Ian N. Bruce:** Conceptualization, Methodology, Writing – review & editing. **Stephen Bianchi:** Conceptualization, Methodology, Investigation, Writing – review &

editing. **Jim M. Wild:** Funding acquisition, Supervision, Writing – review & editing. **Geoff J.M. Parker:** Funding acquisition, Supervision, Writing – review & editing.

Acknowledgements

The research leading to these results received funding from the Innovative Medicines Initiatives 2 Joint Undertaking under grant agreement No 116106. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This work was also supported by the National Institute of Health Research (RP-R3-12-027), Medical Research Council (MR/M008894/1) and GlaxoSmithKline (PJCH.BIDS3000032592). The views expressed are those of the authors and not necessarily those of the NHS, NIHR, the Department of Health, GlaxoSmithKline nor the TRISTAN consortium.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.mri.2022.10.005>.

References

- [1] Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, et al. Drug-induced interstitial lung disease: a systematic review. *J Clin Med* 2018;7:356.
- [2] Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: perspectives in diagnosis and management. *Am J Respir Crit Care Med* 2017;196. <https://doi.org/10.1164/rccm.201611-2201PP>.
- [3] Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. *Am J Respir Crit Care Med* 2013;188. <https://doi.org/10.1164/rccm.201308-1483ST>.
- [4] Ley B, Swigris J, Day B, Stauffer JL, Raimundo K, Chou W, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2017;196. <https://doi.org/10.1164/rccm.201701-0091OC>.
- [5] Bernstein EJ, Jaafar S, Assassi S, Domsic RT, Frech TM, Gordon JK, et al. Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis. *Arthritis & Rheumatology* 2020;72. <https://doi.org/10.1002/art.41415>.
- [6] Weatherley ND, Eaden JA, Stewart NJ, Bartholmai BJ, Swift AJ, Bianchi SM, et al. Experimental and quantitative imaging techniques in interstitial lung disease. *Thorax* 2019;74. <https://doi.org/10.1136/thoraxjnl-2018-211779>.
- [7] Ley B, Collard HR, King Jr TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2011;183:431–40.
- [8] Daccor C, Maher TM. Recent advances in understanding idiopathic pulmonary fibrosis. *F1000Res* 2016;5. <https://doi.org/10.12688/f1000research.8209.1>.
- [9] Weatherley ND, Stewart NJ, Chan H-F, Austin M, Smith LJ, Collier G, et al. Hyperpolarised xenon magnetic resonance spectroscopy for the longitudinal assessment of changes in gas diffusion in IPF. *Thorax* 2019;74. <https://doi.org/10.1136/thoraxjnl-2018-211851>.
- [10] He M, Zha W, Tan F, Rankine L, Fain S, Driehuis B. A comparison of two hyperpolarized ^{129}Xe MRI ventilation quantification pipelines: the effect of signal to noise ratio. *Acad Radiol* 2019;26. <https://doi.org/10.1016/j.acra.2018.08.015>.
- [11] He M, Driehuis B, Que LG, Huang Y-CT. Using hyperpolarized ^{129}Xe MRI to quantify the pulmonary ventilation distribution. *Acad Radiol* 2016;23. <https://doi.org/10.1016/j.acra.2016.07.014>.
- [12] Stewart NJ, Norquay G, Griffiths PD, Wild JM. Feasibility of human lung ventilation imaging using highly polarized naturally abundant xenon and optimized three-dimensional steady-state free precession. *Magn Reson Med* 2015;74. <https://doi.org/10.1002/mrm.25732>.
- [13] Stewart NJ, Chan H, Hughes PJC, Horn FC, Norquay G, Rao M, et al. Comparison of ^3He and ^{129}Xe MRI for evaluation of lung microstructure and ventilation at 1.5 T. *J Magn Reson Imaging* 2018;48:632–42.
- [14] Kern AL, Gutberlet M, Qing K, Voskrebenezov A, Klimeš F, Kaireit TF, et al. Regional investigation of lung function and microstructure parameters by localized ^{129}Xe chemical shift saturation recovery and dissolved-phase imaging: a reproducibility study. *Magn Reson Med* 2019;81. <https://doi.org/10.1002/mrm.27407>.
- [15] Kaushik SS, Robertson SH, Freeman MS, He M, Kelly KT, Roos JE, et al. Single-breath clinical imaging of hyperpolarized ^{129}Xe in the airspaces, barrier, and red blood cells using an interleaved 3D radial 1-point dixon acquisition. *Magn Reson Med* 2016;75. <https://doi.org/10.1002/mrm.25675>.
- [16] Collier GJ, Eaden JA, Hughes PJC, Bianchi SM, Stewart NJ, Weatherley ND, et al. Dissolved ^{129}Xe lung MRI with four-echo 3D radial spectroscopic imaging: quantification of regional gas transfer in idiopathic pulmonary fibrosis. *Magn Reson Med* 2021;85. <https://doi.org/10.1002/mrm.28609>.
- [17] Kern AL, Vogel-Claussen J. Hyperpolarized gas MRI in pulmonology. *Br J Radiol* 2018. <https://doi.org/10.1259/bjr.20170647>.

- [18] Renne J, Lauerermann P, Hinrichs J, Schönfeld C, Sorrentino S, Gutberlet M, et al. Clinical use of oxygen-enhanced T₁ mapping MRI of the lung: reproducibility and impact of closed versus loose fit oxygen delivery system. *J Magn Reson Imaging* 2015;41. <https://doi.org/10.1002/jmri.24535>.
- [19] Edelman RR, Hatabu H, Tadamura E, Li W, Prasad P. V noninvasive assessment of regional ventilation in the human lung using oxygen-enhanced magnetic resonance imaging. *Nat Med* 1996;2:1236–9. <https://doi.org/10.1038/nm1196-1236>.
- [20] Martini K, Gygax CM, Benden C, Morgan AR, Parker GJM, Frauenfelder T. Volumetric dynamic oxygen-enhanced MRI (OE-MRI): comparison with CT Brody score and lung function in cystic fibrosis patients. *Eur Radiol* 2018;28:4037–47. <https://doi.org/10.1007/s00330-018-5383-5>.
- [21] Ohno Y, Yui M, Yoshikawa T, Seki S, Takenaka D, Kassai Y, et al. 3D oxygen-enhanced MRI at 3T MR system: comparison with thin-section CT of quantitative capability for pulmonary functional loss assessment and clinical stage classification of COPD in smokers. *J Magn Reson Imaging* 2021;53:1042–51. <https://doi.org/10.1002/jmri.27441>.
- [22] Triphan SMF, Stahl M, Jobst BJ, Sommerburg O, Kauczor H, Schenk J, et al. Echo time-dependence of observed lung <sc> T₁ </sc> in patients with cystic fibrosis and correlation with clinical metrics. *J Magn Reson Imaging* 2020;52. <https://doi.org/10.1002/jmri.27271>.
- [23] Triphan SMF, Jobst BJ, Anjorin A, Sedlaczek O, Wolf U, Terekhov M, et al. Reproducibility and comparison of oxygen-enhanced T₁ quantification in COPD and asthma patients. *PLOS ONE* 2017;12. <https://doi.org/10.1371/journal.pone.0172479>.
- [24] <https://www.imi-tristan.eu/TRISTAN>.
- [25] American Thoracic Society. European Respiratory Society American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) Was Adopted by the ATS Board of Directors, June 2001 and by the ERS Executive Committee, June 2001. *Am J Respir Crit Care Med* 2002;165:277–304. <https://doi.org/10.1164/ajrccm.165.2.ats01>.
- [26] Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby T, Galvin JR, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner society white paper. *Lancet Respir Med* 2018;6:138–53. [https://doi.org/10.1016/S2213-2600\(17\)30433-2](https://doi.org/10.1016/S2213-2600(17)30433-2).
- [27] Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J* 2005;26:319–38.
- [28] Norquay G, Collier GJ, Rao M, Stewart NJ, Wild JM. Xe 129-Rb spin-exchange optical pumping with high photon efficiency. *Phys Rev Lett* 2018;121:153201.
- [29] Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. *Eur Respir J* 2017;49:1600016.
- [30] Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-Yr age range: the global lung function 2012 equations. *Eur Respir J* 2012;40. <https://doi.org/10.1183/09031936.00080312>.
- [31] Hughes PJC, Horn FC, Collier GJ, Biancardi A, Marshall H, Wild JM. Spatial fuzzy C-means thresholding for Semiautomated calculation of percentage lung ventilated volume from hyperpolarized gas and 1H MRI. *J Magn Reson Imaging* 2018;47:640–6.
- [32] Smith LJ, Horsley A, Bray J, Hughes PJC, Biancardi A, Norquay G, et al. The assessment of short- and long-term changes in lung function in cystic fibrosis using ¹²⁹Xe MRI. *Eur Respir J* 2020;56:2000441. <https://doi.org/10.1183/13993003.00441-2020>.
- [33] Ulloa J, Morgan A, Parker G. Evaluation of whole lung 3D dynamic oxygen-enhanced MRI. *Eur Respir J* 2014;44:1724.
- [34] Zhang W-J, Niven RM, Young SS, Liu Y-Z, Parker GJM, Naish JH. Dynamic oxygen-enhanced magnetic resonance imaging of the lung in asthma—initial experience. *Eur J Radiol* 2015;84:318–26.
- [35] Woodhouse N, Wild JM, Paley MNJ, Fischele S, Said Z, Swift AJ, et al. Combined Helium-3/proton magnetic resonance imaging measurement of ventilated lung volumes in smokers compared to never-smokers. *Journal of Magnetic Resonance Imaging: An Official Journal of the International Society for Magnetic Resonance in Medicine* 2005;21:365–9.
- [36] Maunder A, Rao M, Robb F, Wild JM. Optimization of steady-state free precession MRI for lung ventilation imaging with 19F C3F8 at 1.5 T and 3T. *Magn Reson Med* 2019;81:1130–42.
- [37] Avants BB, Tustison NJ, Stauffer M, Song G, Wu B, Gee JC. The insight ToolKit image registration framework. *Frontiers in Neuroinformatics* 2014;8. <https://doi.org/10.3389/fninf.2014.00044>.
- [38] Morgan AR, Parker GJM, Roberts C, Buonaccorsi GA, Maguire NC, Hubbard Cristinacce PL, et al. Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD. *Eur J Radiol* 2014;83. <https://doi.org/10.1016/j.ejrad.2014.08.004>.
- [39] Dietrich O, Gaass T, Reiser MF. T₁ relaxation time constants, influence of oxygen, and the oxygen transfer function of the human lung at 1.5 T—A Meta-analysis. *Eur J Radiol* 2017;86. <https://doi.org/10.1016/j.ejrad.2016.11.027>.
- [40] Zha W, Kruger SJ, Johnson KM, Cadman Rv, Bell LC, Liu F, et al. Pulmonary ventilation imaging in asthma and cystic fibrosis using oxygen-enhanced 3D radial ultrashort Echo time MRI. *J Magn Reson Imaging* 2018;47. <https://doi.org/10.1002/jmri.25877>.
- [41] Virgincar RS, Cleveland ZI, Sivaram Kaushik S, Freeman MS, Nouis J, Cofer GP, et al. Quantitative analysis of hyperpolarized ¹²⁹Xe ventilation imaging in healthy volunteers and subjects with chronic obstructive pulmonary disease. *NMR Biomed* 2013;26:424–35.
- [42] Kindvall SSI, Diaz S, Svensson J, Wollmer P, Slusarczyk D, Olsson LE. Influence of age and sex on the longitudinal relaxation time, T₁, of the lung in healthy never-smokers. *J Magn Reson Imaging* 2016;43:1250–7.
- [43] Stadler A, Jakob PM, Griswold M, Stiebellehner L, Barth M, Bankier AA. T₁ mapping of the entire lung parenchyma: influence of respiratory phase and correlation to lung function test results in patients with diffuse lung disease. *Magn Reson Med* 2008;59:96–101. <https://doi.org/10.1002/mrm.21446>.
- [44] Magee AL, Montner SM, Husain A, Adegunsoye A, Vij R, Chung JH. Imaging of hypersensitivity pneumonitis. *Radiol Clin North Am* 2016;54:1033–46. <https://doi.org/10.1016/j.rcl.2016.05.013>.
- [45] Kaushik SS, Freeman MS, Yoon SW, Liljeroth MG, Stiles JV, Roos JE, et al. Measuring diffusion limitation with a perfusion-limited gas—hyperpolarized ¹²⁹Xe gas-transfer spectroscopy in patients with idiopathic pulmonary fibrosis. *J Appl Physiol* 2014;117. <https://doi.org/10.1152/jappphysiol.00326.2014>.
- [46] Weatherley ND, Eaden JA, Hughes PJC, Austin M, Smith L, Bray J, et al. Quantification of pulmonary perfusion in idiopathic pulmonary fibrosis with first pass dynamic contrast-enhanced perfusion MRI. *Thorax* 2021;76. <https://doi.org/10.1136/thoraxjnl-2019-214375>.